Sort   by:  
 Page size 
UnknownRandomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
Not available
S-EPMC3574266 | biostudies-literature
UnknownPhase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Not available
S-EPMC3867644 | biostudies-literature
TranscriptomicsTranscription profiling of C. elegans after infection with Microbacterium nematophilum
Genomic response of C. elegans after infection with Microbacterium nematophilum.

The interaction between the nematode Caenorhabditis elegans and a Gram-positive bacterial pathogen, Microbacterium nematophilum, provides a model for an innate immune response in nematodes. This pathogen adheres ...
ORGANISM(S): Caenorhabditis elegans 
2005-01-01 | E-MEXP-696 | biostudies-arrayexpress
UnknownRandomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Not available
S-EPMC4451176 | biostudies-literature
UnknownUS Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Not available
S-EPMC4966513 | biostudies-literature
UnknownSafety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Not available
S-EPMC4878046 | biostudies-literature
GenomicsHigh density copy number analysis and whole exome sequencing of diffuse large B-cell lymphoma

Diffuse Large B-cell Lymphoma (DLBCL) represents the most common form of B-cell non-Hodgkin Lymphoma (B-NHL), accounting for ~30% of the de-novo diagnoses and also arising as a frequent clinical evolution of Follicular Lymphoma (FL). The molecular pathogenesis of DLBCL is associated with multip...

phs000328.v1.p1 | EGA
Sort   by:  
 Page size